Minerva Neurosciences Inc represents values and a corporate philosophy focused on advancing therapies for patients with central nervous system disorders. With a strong commitment to science and innovation, the company strives to develop groundbreaking treatments that can improve the lives of individuals suffering from conditions such as schizophrenia, major depressive disorder, and Parkinson's disease. By leveraging cutting-edge research and collaborating with leading experts in the field, Minerva Neurosciences Inc aims to provide hope and relief to patients worldwide.

Minerva Neurosciences Inc is primarily present in the United States.

Minerva Neurosciences Inc has achieved significant milestones in its operations. Some of these achievements include successful completion of clinical trials for its lead compound MIN-101 in patients with schizophrenia, demonstrating effectiveness and tolerability. The company has also received FDA breakthrough therapy designation for MIN-101, recognizing its potential in addressing unmet medical needs. Furthermore, Minerva Neurosciences has successfully completed Phase IIb clinical trials for MIN-202 in treating major depressive disorder. These accomplishments highlight the company's commitment to developing innovative therapies for psychiatric and neurological diseases, solidifying its position in the healthcare industry.

Minerva Neurosciences Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of innovative therapies to treat central nervous system (CNS) disorders. Founded in 2007 and headquartered in Waltham, Massachusetts, Minerva Neurosciences aims to address unmet medical needs by advancing its diverse portfolio of therapeutic candidates, targeting conditions such as insomnia, major depressive disorder, Parkinson's disease, and schizophrenia. With a commitment to improving patients' lives, Minerva Neurosciences leverages its scientific expertise and collaborations to drive advancements in CNS therapies.

The main competitors of Minerva Neurosciences Inc in the market include companies such as AC Immune SA, Axsome Therapeutics Inc, Intra-Cellular Therapies Inc, and Sage Therapeutics Inc.

Minerva Neurosciences Inc is primarily active in the biotechnology industry.

The business model of Minerva Neurosciences Inc revolves around the development and commercialization of innovative therapies for neuropsychiatric diseases. As a clinical-stage biopharmaceutical company, Minerva focuses on discovering and developing novel drug candidates targeting specific neurotransmitter systems to address unmet medical needs. By leveraging its expertise in neuroscience, Minerva aims to deliver transformative treatments to patients suffering from conditions such as major depressive disorder, schizophrenia, and Parkinson's disease. Through strategic partnerships and collaboration with leading research institutions, Minerva Neurosciences Inc strives to advance the field of neuropsychiatry and improve the lives of individuals affected by these disorders.

Коефициентът на цена спрямо печалбата (КЦП) на Minerva Neurosciences е -1,09.

Коефициентът на цена към оборот (KUV) на Minerva Neurosciences е 0,86.

AlleAktien качественият резултат за Minerva Neurosciences е 3/10.

очаквана Minerva Neurosciences оборотът е 20,40 млн. USD.

очаквана Minerva Neurosciences печалба е -16,11 млн. USD.

Minerva Neurosciences Inc. is a biopharmaceutical company that focuses on developing therapies for central nervous system (CNS) disorders. The company's business model includes research, development, clinical trials, and marketing of medications. The company has a variety of products in the pipeline that are being developed for the treatment of CNS disorders. These include the neuroleptic MIN-101 for the treatment of schizophrenia, the antidepressant MIN-117 for the treatment of depression, the antipsychotic MIN-202 for the treatment of schizophrenia, and the sedative MIN-301 for the treatment of sleep disorders and anxiety. Minerva Neurosciences utilizes a combination of in-house research and partnerships to explore and develop the potential of new medications. The company has a strong R&D team that collaborates closely with academic institutions and other companies to advance research and develop new therapies. To demonstrate the effectiveness of its medications, Minerva Neurosciences has conducted clinical trials examining the impact of its medications on a variety of CNS disorders. The results of these studies have been published in reputable scientific journals and have shown promising results for Minerva Neurosciences' medications. An important feature of Minerva Neurosciences' business model is its partnership strategy. The company works closely with partners from the biopharmaceutical industry and academic institutions to develop new therapies. These partnerships allow Minerva Neurosciences to leverage its resources more effectively and accelerate its research and development efforts. As a biopharmaceutical company, Minerva Neurosciences also relies on investor support. The company utilizes various funding options to finance its research and development efforts, including the sale of stocks, bonds, and government grants. Overall, Minerva Neurosciences Inc.'s business model is focused on developing new medications for the treatment of CNS disorders that have historically been difficult to treat. The company relies on a combination of internal research and collaboration with external partners to achieve this goal. Through this approach, Minerva Neurosciences can develop innovative therapies that can improve the lives of millions of people worldwide.

Minerva Neurosciences разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Minerva Neurosciences в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Minerva Neurosciences е US6033801068.

WKN на Minerva Neurosciences е A1171S.

Тикерът на Minerva Neurosciences е NERV.

През последните 12 месеца Minerva Neurosciences изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Minerva Neurosciences да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Minerva Neurosciences в момента е .

Minerva Neurosciences изплаща дивидент на тримесечие. Той се разпределя в месеците .

Minerva Neurosciences платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Minerva Neurosciences се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Minerva Neurosciences на 3.10.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 3.10.2024 г..

Последното дивидентно плащане беше извършено на 3.10.2024 г..

През година 2023 Minerva Neurosciences изплати 0 USD под формата на дивиденти.

Дивидентите от Minerva Neurosciences се изплащат в USD.